The American Association for the Study of Liver Diseases recently held its Liver Meeting, where new updates on liver health were discussed. One of the key highlights was the latest data on the drug resmetirom, also known as Rezdiffra, developed by Madrigal. This daily pill received accelerated FDA approval last year and is being closely monitored for its effects on outcomes such as MELD score and liver-related mortality. While the full results from the MAESTRO-NASH OUTCOMES study are not expected until 2027, the presentation emphasized the importance of consistent treatment for patients taking MASH to maintain its benefits.
Unfortunately, further details on this topic are restricted to STAT+ subscribers. To access the full article and receive in-depth analysis, newsletters, premium events, and news alerts, you can subscribe to STAT+.
In the meantime, stay tuned for more updates on liver health and the latest advancements in the field. Remember to take care of your liver by maintaining a healthy lifestyle and seeking medical advice if needed. Stay warm during the cold weather and enjoy a hot beverage as you catch up on the latest liver news.
